Evidence map›Paper›PMID 36362882›Full record

ArticleLife (Basel, Switzerland)2022

The Added Value of [

Antonio Piras, Riccardo Laudicella, Luca Boldrini, Andrea D'Aviero, Antonella Sanfratello, Antonino La Rocca, Salvatore Scurria, Giuseppe Salamone, Pierpaolo Alongi, Tommaso Angileri and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Antonio PirasUO Radioterapia Oncologica, Villa Santa Teresa, 90011 Bagheria, Italy.ORCID 0000-0003-2361-9327
Riccardo LaudicellaUO Medicina Nucleare, Fondazione Istituto G. Giglio, 90015 Cefalù, Italy.ORCID 0000-0002-2842-0301
Luca BoldriniUOC Radioterapia Oncologica-Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, 00168 Roma, Italy.ORCID 0000-0002-5631-1575
Andrea D'AvieroRadiation Oncology, Mater Olbia Hospital, 07026 Olbia, Italy.
Antonella SanfratelloUniversità degli Studi di Palermo, Radioterapia Oncologica, 90133 Palermo, Italy.
Antonino La RoccaUOC Urologia, P.O. Paolo Borsellino, 91025 Marsala, Italy.
Salvatore ScurriaUOC Urologia, Azienda di Rilievo Nazionale ad Alta Specializzazione "Civico Di Cristina Benfratelli", 90127 Palermo, Italy.
Giuseppe SalamoneUOC Chirurgia Urologica, Fondazione Istituto G. Giglio, 90015 Cefalù, Italy.
Pierpaolo AlongiUO Medicina Nucleare, Fondazione Istituto G. Giglio, 90015 Cefalù, Italy.
Tommaso AngileriUO Radiologia, Villa Santa Teresa, 90011 Bagheria, Italy.
Antonino DaidoneUO Radioterapia Oncologica, Villa Santa Teresa, 90011 Bagheria, Italy.
Fondazione Istituto G. Giglio di Cefalù · ITAgostino Gemelli University Polyclinic · ITAzienda di Rilievo Nazionale ed Alta Specializzazione · ITUniversity of Messina · ITUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the management of prostate cancer (PCa), correct staging is crucial in order to assess the right therapeutic approach. [

Indexed as

[18F]Choline PET/CTprostate cancerradiotherapy

Identifiers

PMID36362882
PMCPMC9694330
OpenAlexW4307940474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.